Verastem Inc (VSTM)

Low Grade Serous Ovarian Cancer · registered primary completion 2028-10-15 · NCT06072781

Published 2026-09-02Market cap $654M9 sourced statements

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer · PHASE3 · n=270 · recruiting

What this sheet is scored on

call

Cash of $152M against operating outflow of $41M per quarter gives roughly 3.8 quarters of runway against a registered primary completion 8.6 quarters out. On these figures the company raises capital within four quarters.

Source: 10-Q filed 2026-08-06

Balance sheet

fact

Management has concluded there is substantial doubt about the company's ability to continue as a going concern.

Source: 10-Q filed 2026-08-06

“ing costs to execute its strategic plan, including costs related to research and development of its product candidates and commercial activities. As a result of the assessment in accordance with the applicable accounting standards, these conditions raise substantial doubt about the Company's ability to continue as a going concern for twelve months after the date the condensed consolidated financial statements ar…”

Market

fact

1 approved product already carry Low Grade Serous Ovarian Cancer on label, including AVMAPKI FAKZYNJA CO-PACK. Approval would enter an occupied market.

Source: FDA label index

Trial registry

fact

Registered design for NCT06072781: randomized, open-label, 270 participants (estimated). Primary outcome: Progression Free Survival (PFS) per blinded independent central review (BICR).

Source: ClinicalTrials.gov record

Share count and dilution

fact

90,563,441 shares outstanding against 97,623,930 if every outstanding option, warrant and convertible were exercised. In that case 7.2% of a gain in enterprise value would accrue to those holders rather than to current shareholders.

Source: antidilutive-securities disclosure, 10-Q filed 2026-08-06

fact

Share count up 47% year over year to 90,563,441 as of 2026-08-03.

Source: cover-page share counts (XBRL)

Regulatory

fact

Designations disclosed: Breakthrough Therapy, Fast Track, Orphan Drug. These accelerate review and, for Orphan, confer exclusivity if approved; none is evidence of efficacy.

Source: 10-Q filed 2026-08-06

Pipeline

fact

13 distinct molecules in 10 active company-sponsored trials; avutometinib accounts for 1 of them at Phase 3.

Source: ClinicalTrials.gov, company as lead sponsor

Ownership and proceedings

fact

Directors and executive officers as a group hold 1.94%.

Source: DEF 14A filed 2026-04-09

Don't see a name? Request a sheet. Any US-listed biotech with a Phase 3 or a pending FDA decision — it gets built the same way, from the filings.

This sheet is dated and will not be edited. When the registered primary completion passes, its outcome is recorded on the scoreboard and a new dated sheet is published if the filings change materially.